Clinical Trial Update: Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) [Phase 2]

View source ↗

Summary

A Phase 2 trial (VIKTORY-2) is evaluating the combination of savolitinib and durvalumab in MET-amplified advanced gastric cancer and is currently recruiting. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Savolitinib (savolitinib)

Snippet

Sponsor: Jeeyun Lee | Conditions: Stomach Cancer, Adenocarcinoma | Phase 2 | Status: RECRUITING